Orion Corporation, Orion Pharma [clinicaltrials_resource:56914c11ae481d6452d21ddca88db97d]
Merja Mäkitalo [clinicaltrials_resource:0a30f9937f1ccf270bec333f668aeb78]Leena Mattila, MD, PhD [clinicaltrials_resource:0eb74785b905b8f485d5eae4f6497d8a]Ulla Sairanen, MSc [clinicaltrials_resource:146705cac76067974b9b11cf4b252304]Abraham Kroon, MD, PhD [clinicaltrials_resource:1526800ff7e961797416facd992a3b32]Merja Mäkitalo [clinicaltrials_resource:1b4fed4a7398764a6622b50c4e262ef2]Irja Korpela [clinicaltrials_resource:1fbd579bcfbdd93292b4ecc3602e0cc1]Johanna Hietamäki, MSc [clinicaltrials_resource:30f323a8f43670d046e28372dcac7f26]Aila Holopainen, M.Sc. [clinicaltrials_resource:3dbbedfe0021379df75628ead2a9ec7d]Merja Mäkitalo [clinicaltrials_resource:7d24b988dd6d445e639ac848dccc4616]Kati Kaijasilta [clinicaltrials_resource:81dd6727cf31e1f6398e76567fdc7072]Irja Korpela, MSc [clinicaltrials_resource:a3939c4ca11f46000d8ba84d21b55bd3]Satu Lähelmä, M.Sc.(Pharm) [clinicaltrials_resource:adbc7383f6be90600e958732cf22f46f]Kimmo Ingman, MD, PhD [clinicaltrials_resource:b8a344b3cccd9705603ab53047a06c71]Jutta Hänninen, M.Sc. [clinicaltrials_resource:be13df757c135dca28862923ac608ff4]Andrew Wighton, BSc (Hons) [clinicaltrials_resource:c402d5782a4e7c5908739a65d118be37]Merja Mäkitalo [clinicaltrials_resource:fa68561f0567798d5c152da299ca5ee0]Kimmo Ingman [clinicaltrials_resource:fea97cf86a2f046a62a27b411cc7487c]
affiliation [clinicaltrials_vocabulary:affiliation]
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer [clinicaltrials:NCT01317641]clinicaltrials:NCT01783132Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer [clinicaltrials:NCT01784757]Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects [clinicaltrials:NCT02418650]clinicaltrials:NCT02432664clinicaltrials:NCT02471196
collaborator [clinicaltrials_vocabulary:collaborator]
Stalevo in Early Wearing-Off Patients [clinicaltrials:NCT00125567]Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass [clinicaltrials:NCT00130871]Peroral Levosimendan in Chronic Heart Failure [clinicaltrials:NCT00130884]Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients. [clinicaltrials:NCT00219388]Dexmedetomidine for Continuous Sedation [clinicaltrials:NCT00226785]Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off. [clinicaltrials:NCT00247247]Study to Evaluate Initiation of Stalevo in Early Wearing-off [clinicaltrials:NCT00462007]Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU) [clinicaltrials:NCT00479661]Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU) [clinicaltrials:NCT00481312]PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding [clinicaltrials:NCT00562198]clinicaltrials:NCT00603681Safety and Tolerability Study With Single Ascending Doses of ORM-12741 [clinicaltrials:NCT00693316]Pharmacokinetic Study With Repeated Doses of Stalevo [clinicaltrials:NCT00693862]Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables [clinicaltrials:NCT00698763]Suitability of 11C-ORM-13070 as a PET Tracer [clinicaltrials:NCT00735774]Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU [clinicaltrials:NCT00747721]Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741 [clinicaltrials:NCT00792493]Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741 [clinicaltrials:NCT00817544]Pharmacokinetic Study of ORM-12741 in Healthy Volunteers [clinicaltrials:NCT00818740]A PET Study With ORM-12741 [clinicaltrials:NCT00829907]Early Phase I Microdosing Study of ORM-14540 and ORM-12741 [clinicaltrials:NCT00831077]Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis [clinicaltrials:NCT00846235]Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler [clinicaltrials:NCT00868426]Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions [clinicaltrials:NCT00878514]Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets [clinicaltrials:NCT00878865]Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics [clinicaltrials:NCT00964535]Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler Inhalers [clinicaltrials:NCT00984906]Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741 [clinicaltrials:NCT01068028]Levodopa Concentration Profile With Stalevo 75/125 mg [clinicaltrials:NCT01070628]Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets [clinicaltrials:NCT01083290]Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers [clinicaltrials:NCT01181063]Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens [clinicaltrials:NCT01296464]Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon [clinicaltrials:NCT01315899]Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer [clinicaltrials:NCT01317641]Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease [clinicaltrials:NCT01324518]Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler [clinicaltrials:NCT01386996]Phase I Pharmacokinetic Study (BF-BLOCK) [clinicaltrials:NCT01423305]Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF) [clinicaltrials:NCT01424137]Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001 [clinicaltrials:NCT01429064]Pharmacokinetic Pilot Study on Budesonide/Formoterol [clinicaltrials:NCT01457716]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Jutta Hänninen, Clinical Study Manager, Orion Corporation, Orion Pharma [clinicaltrials_resource:03d7d32ccb67a28d28916d9c66e1e3df]Jutta Hänninen / Clinical Study Manager, Orion Corporation, Orion Pharma [clinicaltrials_resource:0f82bcdb2f53d671b2ba7cfce0f96efd]Ulla Sairanen, Orion Corporation, Orion Pharma [clinicaltrials_resource:15dd3689d18a79c4127363076b29e755]Satu Lähelmä/Clinical Study Director, Orion Corporation, Orion Pharma [clinicaltrials_resource:1a524f266a0a459ec33bbcf7f1f3f743]Orion Corporation, Orion Pharma (Leena Lehtonen, Clinical study director), Orion Corporation, Orion Pharma [clinicaltrials_resource:283b7b05a7955e36b24e27e112b91c6b]MD, PH.D. Kimmo Ingman, Orion Corporation, Orion Pharma [clinicaltrials_resource:3fc4c53c894718a8fc0e490294c10577]Ulla Sairanen, Clinical study director, Orion Corporation, Orion Pharma [clinicaltrials_resource:98ab8ed95bee77414c93fbd0ab7ad8ef]Andrew Wighton, Orion Corporation, Orion Pharma [clinicaltrials_resource:c679a11354dd21eb0e5239f426b32936]
organization [clinicaltrials_vocabulary:organization]
Stalevo in Early Wearing-Off Patients [clinicaltrials:NCT00125567]Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass [clinicaltrials:NCT00130871]Peroral Levosimendan in Chronic Heart Failure [clinicaltrials:NCT00130884]Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients. [clinicaltrials:NCT00219388]Dexmedetomidine for Continuous Sedation [clinicaltrials:NCT00226785]Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off. [clinicaltrials:NCT00247247]Study to Evaluate Initiation of Stalevo in Early Wearing-off [clinicaltrials:NCT00462007]Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU) [clinicaltrials:NCT00479661]Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU) [clinicaltrials:NCT00481312]PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding [clinicaltrials:NCT00562198]clinicaltrials:NCT00603681Safety and Tolerability Study With Single Ascending Doses of ORM-12741 [clinicaltrials:NCT00693316]Pharmacokinetic Study With Repeated Doses of Stalevo [clinicaltrials:NCT00693862]Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables [clinicaltrials:NCT00698763]Suitability of 11C-ORM-13070 as a PET Tracer [clinicaltrials:NCT00735774]Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU [clinicaltrials:NCT00747721]Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741 [clinicaltrials:NCT00792493]Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741 [clinicaltrials:NCT00817544]Pharmacokinetic Study of ORM-12741 in Healthy Volunteers [clinicaltrials:NCT00818740]A PET Study With ORM-12741 [clinicaltrials:NCT00829907]Early Phase I Microdosing Study of ORM-14540 and ORM-12741 [clinicaltrials:NCT00831077]Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis [clinicaltrials:NCT00846235]Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler [clinicaltrials:NCT00868426]Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions [clinicaltrials:NCT00878514]Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets [clinicaltrials:NCT00878865]Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics [clinicaltrials:NCT00964535]Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler Inhalers [clinicaltrials:NCT00984906]Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741 [clinicaltrials:NCT01068028]Levodopa Concentration Profile With Stalevo 75/125 mg [clinicaltrials:NCT01070628]Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets [clinicaltrials:NCT01083290]Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers [clinicaltrials:NCT01181063]Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens [clinicaltrials:NCT01296464]Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon [clinicaltrials:NCT01315899]Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer [clinicaltrials:NCT01317641]Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease [clinicaltrials:NCT01324518]Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler [clinicaltrials:NCT01386996]Phase I Pharmacokinetic Study (BF-BLOCK) [clinicaltrials:NCT01423305]Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF) [clinicaltrials:NCT01424137]Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001 [clinicaltrials:NCT01429064]Pharmacokinetic Pilot Study on Budesonide/Formoterol [clinicaltrials:NCT01457716]
source [clinicaltrials_vocabulary:source]
Orion Corporation, Orion Pharma [clinicaltrials_resource:56914c11ae481d6452d21ddca88db97d]
Bio2RDF identifier
56914c11ae481d6452d21ddca88db97d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:56914c11ae481d6452d21ddca88db97d
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:56914c11ae481d6452d21ddca88db97d
title
Orion Corporation, Orion Pharma
@en
type
label
Orion Corporation, Orion Pharm ...... 14c11ae481d6452d21ddca88db97d]
@en